Novartis agreed to license a preclinical amyloid-targeting Alzheimer’s program from SciNeuro with a $165 million upfront payment and a joint early-development plan. The deal gives Novartis rights to advance the candidate through early stages and take lead development thereafter, while SciNeuro retains collaboration terms for initial work. The transaction links a major Swiss drugmaker with a small neuroscience developer focused on amyloid biology, signaling continued industry interest in amyloid-targeting strategies despite mixed clinical histories. The structured upfront and joint-development model spreads preclinical risk and accelerates candidate advancement into IND-enabling studies.